RecruitingNCT07245407
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Principal Investigator
- Jinfu Xu, DoctorShanghai Tongji Hospital, Tongji University School of Medicine
- Intervention
- Participant Follow-up(other)
- Enrollment
- 320 enrolled
- Eligibility
- All sexes
- Timeline
- 2025 – 2027
Study locations (30)
- Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, Beijing Municipality, China
- Beijing Hospital, Beijing, Beijing Municipality, China
- Peking University People's Hospital, Beijing, Beijing Municipality, China
- The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
- Gansu Provincial Hospital, Lanzhou, Gansu, China
- Shenzhen People's Hospital, Shenzhen, Guangdong, China
- Affiliated Hospital of Guangdong Medical University", Zhanjiang, Guangdong, China
- The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
- Henan Provincial People's Hospital, Zhengzhou, Henan, China
- Zhengzhou People's Hospital, Zhengzhou, Henan, China
- Shiyan Taihe Hospital, Shiya, Hubei, China
- Xiangya Hospital of Central South University, Changsha, Hunan, China
- The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07245407 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS